target
porcin
immun
systemparticul
vaccin
centuri
ideal
scenario
efficaci
vaccin
requir
initi
potent
immun
respons
vaccin
formul
resembl
situat
natur
infect
realiti
vaccin
manufactur
resembl
close
possibl
pathogen
question
lack
pathogen
natur
elabor
approach
sought
dissect
vaccin
pertin
immunogen
compon
promot
protect
immun
defenc
viru
vaccin
base
whole
viru
approach
includ
applic
attenu
variant
well
inactiv
antigen
moreov
studi
evolut
vaccin
design
combat
viral
infect
show
manipul
vaccin
composit
increas
success
rate
gener
efficaci
vaccin
appreci
approach
evolut
show
three
main
element
essenti
success
vaccin
antigen
characterist
vaccin
ii
mode
vaccin
deliveri
last
decad
often
ignor
releg
posit
alsoran
particular
signific
effici
vaccin
deliveri
relat
directli
vaccin
profici
target
host
immun
system
iii
adjuv
applic
major
tool
often
critic
import
compon
efficaci
vaccin
major
provid
danger
signal
necessari
activ
innat
respons
essenti
promot
efficaci
specif
immun
defenc
although
virus
bacteri
compon
provid
danger
signal
may
requir
effici
replic
pathogen
possibl
inactiv
subunit
vaccin
altern
week
danger
signal
may
provid
due
lowlevel
interact
appropri
receptor
presenc
inhibitori
signal
overal
vaccin
must
effici
deliv
appropri
compart
immun
system
lead
correct
signal
immun
system
process
vaccin
promot
efficaci
vaccin
accordingli
import
issu
vaccin
design
consider
ligand
carri
number
pathogen
interact
receptor
cell
immun
system
adjuv
also
contain
compon
interact
immun
cell
particularli
innat
immun
defenc
respect
involv
dendrit
cell
dc
crucial
due
role
central
player
immun
defenc
develop
supplementari
fig
dc
ensur
appropri
recognit
danger
signal
correct
process
vaccin
antigen
promot
efficaci
develop
innat
acquir
immun
defenc
order
appreci
vaccin
target
immun
system
enhanc
efficaci
necessari
development
base
promis
ration
design
vaccin
platform
current
review
provid
updat
particlebas
vaccin
viral
synthet
origin
give
exampl
recombin
viru
carrier
adenovirus
biodegrad
particul
carrier
viral
carrier
carri
pathogenassoci
molecular
pattern
pamp
use
origin
viru
target
dc
particularli
effici
versatil
gene
deliveri
vector
effort
field
synthet
vaccin
carrier
focuss
decor
particl
surfac
ligand
dc
receptor
heparan
sulphat
glycosaminoglycan
structur
integrin
siglec
galectin
ctype
lectin
tolllik
receptor
emphasi
review
place
target
porcin
immun
system
refer
made
advanc
murin
human
vaccin
deliveri
system
inform
dc
target
avail
elsevi
ltd
right
reserv
appreci
central
role
play
dc
therein
critic
target
vaccin
deliveri
supplementari
fig
inactiv
proteinbas
vaccin
induc
acquir
specif
immun
respons
involv
mhc
class
iirestrict
thelper
th
b
lymphocyt
antibodydepend
immun
defenc
addit
defenc
import
remov
infect
alter
self
host
cell
involv
mhc
class
irestrict
cytotox
lymphocyt
ctl
respons
although
less
evid
follow
vaccin
inactiv
vaccin
overal
central
key
player
induc
efficaci
acquir
immun
dc
area
cover
detail
elsewher
follow
endocytosi
vaccin
dc
process
antigen
toward
present
deriv
peptid
lymphocyt
associ
either
mhc
class
ii
class
molecul
advanc
murin
rat
immunolog
shown
dc
may
deliv
antigen
intact
form
b
lymphocyt
releas
antigen
stimul
b
lymphocyt
furthermor
dc
releas
cytokin
major
import
b
lymphocyt
activ
type
interferon
ifn
baff
efficaci
vaccin
depend
effici
vaccin
interact
dc
subset
rais
question
vaccin
deliveri
influenc
convent
dc
cdc
plasmacytoid
dc
pdc
well
monocyt
macrophag
becom
involv
dc
possess
broad
spectrum
cell
surfac
receptor
involv
initi
promot
execut
immun
respons
importantli
express
pattern
receptor
vari
cdc
pdc
among
tlr
scaveng
receptor
ctype
lectin
receptor
fig
import
pattern
recognit
receptor
prr
recogn
pamp
pathogen
inde
antigen
adjuv
vaccin
essenti
develop
innat
immun
respons
defenc
pamp
bind
prr
dc
surfac
also
offer
potenti
target
vaccin
deliveri
ligat
particular
prr
evok
rapid
activ
cell
induc
proinflammatori
cytokin
releas
upregul
costimulatori
molecul
leukocyt
seen
dc
macrophag
prr
certain
ctype
lectin
receptor
ligat
lead
enhanc
endocytosi
dc
act
antigenpres
cell
apc
ligat
also
lead
induct
dc
maturationan
essenti
step
licens
cell
induc
potent
effector
well
memori
immun
respons
good
exampl
pamp
ligat
prr
activ
cdc
seen
bacteri
lipopeptid
lipoprotein
recogn
heterodimer
lipopeptid
deliv
strong
activ
signal
dc
basi
potent
activ
immunoadjuv
vitro
vivo
least
rodent
primat
ctype
lectin
prr
multilectin
receptor
mannos
receptor
involv
enhanc
endocytosi
ligat
receptor
also
shown
potenti
vaccin
target
activ
dc
murin
system
ligat
enhanc
receptordepend
endocyt
process
lead
effici
recycl
antigen
late
endosomessuch
process
like
enhanc
antigen
present
helper
lymphocyt
contrast
ligat
mannos
receptor
tend
promot
recycl
peripher
endosom
compart
exampl
target
specif
receptor
dc
result
differ
form
signal
dc
import
consider
target
vaccin
immun
system
depend
receptor
target
antigen
may
deliv
differ
compart
dc
import
consequ
type
immun
respons
induc
consequ
follow
section
use
select
exampl
vaccin
develop
demonstr
vaccin
may
target
immun
system
possibl
exampl
given
porcin
field
elabor
use
gener
advanc
immunolog
character
interact
dc
vaccin
carrier
promot
interact
surfac
receptor
dc
import
element
concept
recombin
vector
vaccin
select
immunogen
structur
pathogen
replac
pathogen
ensur
effici
deliveri
immun
system
form
biolog
activ
carrier
approach
help
reduc
risk
associ
handl
live
pathogen
problem
incomplet
inactiv
revers
attenu
approach
must
ensur
vaccin
retain
high
level
immunogen
difficult
achiev
subunit
proteinpeptid
vaccin
virus
possess
natur
ligand
bind
receptor
cell
infect
receptor
identifi
virus
employ
vaccin
design
fig
although
fig
exampl
known
receptor
dc
may
potenti
target
vaccin
base
work
perform
vaccin
target
dc
analys
ligand
receptor
interact
mani
virus
infect
epitheli
cell
larg
number
interact
directli
dc
particular
monocytotrop
virus
also
restrict
infect
epitheli
cell
immunogen
antigen
transfer
dc
follow
exocytosi
produc
cell
disadvantag
viral
vector
immun
respons
vector
restrict
applic
term
multipl
use
differ
vaccin
howev
format
antibodi
complex
vaccin
certain
advantag
term
immun
reaction
induc
exampl
fcgritarget
adenoviru
vector
enhanc
vectormedi
gene
transfer
human
dc
lead
increas
immun
respons
vectorencod
antigen
vaccinia
viru
one
earliest
virus
employ
vector
gener
recombin
vaccin
gener
speci
recombin
vaccinia
viru
express
influenza
viru
haemagglutinin
test
cattl
sheep
poultri
porcin
front
vaccinia
viru
employ
gener
recombin
vaccin
express
pseudorabi
viru
prv
glycoprotein
overview
report
vaccinia
viru
recombin
employ
vector
porcin
vaccin
given
tabl
includ
recent
applic
recombin
modifi
ankara
vaccinia
viru
tabl
relat
applic
vaccinia
vector
swine
poxviru
also
propos
basi
porcin
recombin
vaccin
tabl
although
test
porcin
vaccin
vector
swine
poxviru
clear
potenti
exampl
work
felin
leukaemia
viru
antigen
infect
porcin
cell
tabl
fowlpox
viru
parapoxviru
orf
viru
employ
vector
potenti
porcin
vaccin
tabl
interestingli
orf
viru
vector
also
display
adjuv
potenti
induc
ifn
respons
tabl
whether
vaccinia
viru
enter
porcin
dc
lead
viral
dna
replic
transcript
uncertain
studi
use
mous
human
cell
appear
viru
interact
dc
date
receptor
involv
defin
although
possibl
propos
potenti
candid
fig
certainli
vaccinia
viru
less
effici
bind
human
dc
compar
human
epitheli
cell
line
jenn
et
al
also
demonstr
difficulti
vaccinia
viru
replic
human
dc
immatur
well
matur
lead
abort
infect
protein
control
late
promot
lack
nevertheless
certain
level
protein
translat
occur
dc
could
promot
antigenspecif
lymphocyt
prolifer
mention
dc
process
antigen
alon
inadequ
effici
promot
immun
respons
induct
dc
matur
also
requir
typic
danger
signal
respect
vaccin
vector
report
absenc
vaccinia
virusinduc
matur
dc
moreov
reduc
express
certain
costimulatori
molecul
mhc
virusinfect
dc
togeth
reduc
capac
stimul
tcell
prolifer
observ
modifi
vaccinia
viru
ankara
even
problemat
human
dc
term
reduc
cellular
protein
synthesi
lead
increas
apoptosi
virusinfect
dc
latter
event
would
advantag
develop
cytotox
immun
crosspresent
apoptot
cell
result
overal
queri
valu
direct
interact
vaccinia
viru
vector
dc
yate
alexandermil
show
vaccinia
viru
infect
immatur
dc
induct
matur
yield
dc
incap
initi
tcell
activ
matur
dc
infect
vaccinia
viru
function
antigenpres
cell
gener
capabl
activ
vaccinia
virusspecif
lymphocyt
moreov
nagorsen
et
al
note
effici
vaccin
viru
vectordeliv
vaccin
depend
hla
haplotyp
epitop
carri
vaccin
nontransmiss
pseudorabi
viru
vector
creat
delet
essenti
gd
requir
prv
penetr
consid
viru
still
spread
celltocel
biolog
safer
quadrupl
glycoproteindelet
prv
lack
gg
gi
ge
gener
prv
vector
vaccin
gener
encod
protein
number
virus
tabl
although
potenti
prv
vector
target
dc
investig
report
capac
prv
infect
replic
effici
macrophag
would
indic
tropism
monocyt
cell
includ
dc
fig
unfortun
report
prv
infect
macrophag
associ
immunolog
malfunct
contrast
prv
seen
potent
activ
porcin
pdc
would
benefici
use
vector
result
show
interact
prv
cdc
pdc
need
character
one
propos
vaccin
deliveri
vehicl
target
dc
inde
result
poxvirus
prv
demonstr
need
understand
type
statu
dc
target
vaccin
carrier
ensur
appropri
process
lead
activ
effector
immun
defenc
adenoviru
receiv
much
attent
vector
deliveri
vaccin
recombin
replicationdefect
adenovirus
gener
number
porcin
pathogen
tabl
effort
employ
primarili
human
adenoviru
serotyp
porcin
adenoviru
serotyp
although
canin
adenoviru
type
also
test
adenovirusvector
antigen
also
produc
cell
cultur
goat
milk
applic
recombin
vaccin
rather
vector
vaccin
although
porcin
adenoviru
might
appear
obviou
candid
choic
applic
human
adenoviru
high
potenti
torr
et
al
analys
effici
vector
target
cell
organ
vaccin
pig
found
adenoviru
antigen
associ
epitheli
cell
bronchiol
macrophag
type
ii
pneumocyt
follicular
dendrit
cell
howev
unclear
whether
adenovirusposit
cell
accommod
replic
viru
therefor
potenti
produc
heterolog
antigen
vector
vaccin
endocytos
antigen
produc
elsewher
human
adenoviru
also
engin
express
immunostimulatori
cytokin
promot
innat
resist
infect
success
exampl
vaccin
footandmouth
diseas
viru
fmdv
recombin
human
adenoviru
express
fmdv
capsid
precursor
protein
proteas
coadminist
adenoviru
express
porcin
ifna
particularli
intrigu
consid
import
type
ifn
matur
cdc
develop
innat
respons
follow
vaccin
mechan
adenovirus
may
interact
dc
infer
studi
employ
human
monocyt
macrophag
human
cell
line
murin
bone
marrowderiv
dc
fig
moreov
immunomodulatori
capac
adenovirus
demonstr
use
murin
bone
mar
rowderiv
dc
term
matur
dc
phenotyp
modif
cytokin
induct
relat
miller
et
al
note
induc
matur
dc
depend
viru
entri
rather
transcript
viral
genom
molinierfrenkel
et
al
identifi
penton
capsom
fibr
protein
knob
domain
major
induc
dc
matur
bontk
et
al
found
adenoviru
alon
poor
infect
human
pdc
contrast
basnertschakarjan
et
al
abl
transduc
murin
bone
marrowderiv
cdc
pdc
adenoviru
lead
cell
matur
product
ifna
effect
observ
pdc
signal
engag
discriminatori
result
adenoviru
interact
dc
subset
may
relat
receptor
requir
differ
adenoviru
serotyp
differ
rodent
human
see
comment
next
paragraph
concern
express
interestingli
target
adenoviru
human
dc
enhanc
viru
engin
express
capsid
bontk
et
al
also
use
target
approach
improv
viru
interact
dc
although
improv
transduct
effici
increas
matur
pdc
straightforward
approach
target
vaccin
dc
would
employ
viru
vector
known
interact
particular
receptor
dc
context
adenovirus
clear
applic
receptor
identifi
human
dc
well
human
murin
monocyt
macrophag
particular
adenovirus
interact
howev
initi
problem
realis
major
cell
receptor
viru
bind
character
coxsackieadenoviru
receptor
car
despit
wide
express
cell
adhes
molecul
receptor
found
dc
monocyt
cell
popul
contrast
anoth
receptor
express
dc
howev
employ
subgroup
b
adenovirus
adenoviru
subgroup
c
adenovirus
wide
appli
vaccin
vector
adenoviru
well
canin
adenoviru
type
vaccin
vector
employ
car
nevertheless
work
shown
import
receptor
vaccin
target
present
mani
subtyp
human
dc
interestingli
express
murin
dc
variat
among
adenoviru
subtyp
respect
receptor
target
would
creat
uncertainti
applic
vector
commonli
employ
adenoviru
yet
vaccin
proven
success
pig
see
tabl
one
explan
may
adenoviru
vector
target
cell
dc
epitheli
cell
express
car
altern
vector
may
use
receptor
car
dc
integrin
complement
receptor
glycosaminoglycan
heparan
sulphat
structur
cell
surfac
may
also
function
adenoviru
receptor
addit
certain
adenovirus
employ
v
integrin
interact
cell
least
cell
line
human
monocyt
macrophag
consid
adenoviru
target
cell
import
bear
mind
viru
interact
cell
surfac
receptor
singl
event
adenoviru
bind
cell
via
fibr
protein
viral
penton
base
interact
cellular
integrin
v
b
v
b
promot
viru
entri
role
penton
base
appear
depend
rgd
motif
five
ident
subunit
least
cell
line
involv
v
integrin
may
import
viru
internalis
attach
cell
yet
modifi
viral
fibr
knob
adenoviru
type
carri
rgd
motif
result
enhanc
infect
murin
dc
interact
viru
fibr
protein
clearli
import
bind
cell
line
penton
base
interact
b
integrin
import
bind
human
monocyt
macrophag
akin
attach
via
fibr
knob
interact
b
integrin
still
requir
addit
step
involv
v
integrin
viru
internalis
addit
integrin
target
adenoviru
interact
cell
surfac
glycosaminoglycan
structur
occur
may
particularli
pertin
consid
v
integrin
effici
express
follow
activ
monocyt
macrophag
dc
wickham
et
al
demonstr
adenoviru
type
modifi
carri
heparan
sulphatebind
heptalysin
motif
effici
transduc
human
monocyt
macrophag
candid
heparinbind
kktk
motif
also
identifi
third
pseudorepeat
fibr
shaft
adenovirus
moreov
mani
virus
bind
heparan
sulphat
structur
cell
particularli
follow
cell
cultur
passag
viru
often
case
produc
vaccin
virus
howev
heparan
sulphat
structur
rather
ubiquit
express
may
ideal
enhanc
dc
target
interact
cell
type
contrari
restrict
cell
innat
immun
system
name
dc
macrophag
monocyt
inde
contrast
adenovirus
type
subgroup
c
adenovirus
adenoviru
type
subgroup
b
requir
heparan
sulphat
glycosaminoglycan
bind
infect
cell
line
modul
vaccin
target
achiev
introduc
ligand
vaccin
deliveri
vehicl
enhanc
target
desir
receptor
adenovirus
provid
interest
exampl
valu
approach
chimer
adenoviru
creat
modifi
subgroup
c
adenoviru
type
carri
subgroup
b
adenoviru
fibr
antigen
increas
interact
human
dc
similar
approach
may
achiev
appli
short
peptid
motif
known
capac
interact
integrin
express
dc
describ
section
one
disadvantag
approach
certain
motif
rgd
potenti
bind
differ
integrin
nevertheless
presenc
rgd
motif
chimer
adenoviru
penton
base
appar
influenc
interact
integrin
suggest
involv
structur
perhap
fibr
antigen
carri
kktk
motif
adenoviru
would
import
inde
perreau
et
al
propos
chimer
virus
could
employ
nonintegrinbind
capac
canin
adenoviru
knob
combin
capac
human
adenoviru
interact
integrin
differ
target
event
would
influenc
dc
handl
vaccin
depend
cell
receptor
target
inde
human
adenoviru
canin
adenoviru
appear
endocytos
distinct
intracellular
compart
role
differ
receptor
lead
distinct
compartmentalis
within
cell
well
influenc
multipl
receptor
involv
import
consider
analys
potenti
target
vaccin
dc
inform
concern
bind
particular
vaccin
dc
less
inform
endocyt
rout
taken
thereaft
unfortun
endocyt
process
determin
antigen
releas
interact
b
lymphocyt
process
mhc
class
ii
th
lymphocyt
process
via
immunoproteasom
present
associ
mhc
class
tc
lymphocyt
endocyt
pathway
employ
also
determin
genet
inform
carri
viral
vector
vaccin
translat
protein
import
issu
rais
later
discuss
ctype
lectin
receptor
target
canin
parvoviru
report
interact
transferrin
receptor
tfr
fig
refer
asymmetr
bind
receptor
molecul
ae
tfr
dimmer
bind
per
capsid
author
suggest
asymmetr
bind
tfr
might
due
viru
possess
one
uniqu
site
conform
bind
tfr
altern
bind
viru
tfr
might
induc
asymmetri
whatev
mechan
bind
differ
associ
picornaviru
infect
site
icosahedron
involv
numer
nonenvelop
virus
includ
fmdv
known
potenti
interact
heparan
sulphat
structur
cell
surfac
heparan
sulphat
structur
dc
import
bind
cellcultur
passag
fmdv
relat
vaccin
virus
fig
viru
also
carri
ligand
integrin
receptor
howev
appear
prefer
integrin
viru
bind
either
express
poorli
express
dc
whether
ligat
heparan
sulphat
structur
best
target
remain
elucid
transmiss
gastroenter
viru
tgev
also
gener
interest
respect
dc
target
addit
tgev
employ
vaccin
vector
review
enjuan
et
al
tgev
effici
induc
ifn
product
pdc
abil
independ
viru
replic
viral
pseudoparticl
express
e
protein
resembl
intact
virion
retain
interferogen
activ
viru
neither
viru
genom
spike
protein
necessari
infect
cell
essenti
ifn
induct
induct
ifn
requir
viru
interact
cell
surfac
virion
structur
import
relat
report
baudoux
et
al
riffault
et
al
shown
antibodi
tgev
receptor
aminopeptidas
n
prevent
ifn
induct
antibodi
surfac
protein
effect
moreov
reconstruct
deterg
solubilis
viru
virosom
reconstitut
ifn
induct
capac
author
conclud
induct
ifn
requir
complex
nativ
envelop
protein
structur
difficult
identifi
receptor
involv
ifn
induct
although
seem
certain
induct
signal
interact
receptor
pdc
surfac
insofar
applic
target
vaccin
dc
one
may
employ
pseudoparticl
express
e
protein
although
influenza
viru
per
se
appli
viral
vector
deriv
virosom
base
influenza
viru
envelop
plu
surfac
glycoprotein
high
potenti
context
viru
biolog
interest
term
dc
target
sialic
residu
cell
particularli
sialic
acid
well
establish
receptor
influenza
virus
effici
virosom
vaccin
carrier
exampl
would
suggest
sialic
acid
dc
least
murin
human
dc
target
vaccin
inde
angel
et
al
demonstr
virosom
interact
pdc
reliant
sialic
acid
structur
cell
surfac
endocytosi
virosom
pdc
inhibit
neuraminidas
treatment
howev
one
also
consid
target
ctype
lectin
mannos
receptor
dc
read
et
al
demonstr
import
mannos
receptor
influenza
viru
infect
murin
macrophag
nevertheless
sialic
acid
residu
dc
would
offer
potenti
vaccin
target
particularli
vaccin
construct
carri
haemagglutinin
glycoprotein
anoth
import
consider
vari
phenotyp
dc
respect
dc
subset
particularli
dc
differenti
matur
sialyl
structur
dc
modul
differenti
interact
b
cell
result
increas
express
oglycan
well
nglycan
interestingli
sialyl
glycan
import
dc
endocyt
activ
matur
dc
result
reduc
express
glycan
relat
reduc
endocyt
activ
matur
dc
altern
approach
use
live
nontransmiss
replic
vaccin
vector
use
viruslik
particl
vlp
lack
viral
genom
physic
carri
vaccin
antigen
interest
within
virion
structur
foreign
vaccin
antigen
within
chimer
structur
replic
longer
necessari
fact
chimer
vector
regard
deliv
vaccin
manner
similar
inactiv
vaccin
chimer
virus
base
nonenvelop
vlp
also
defin
term
structur
sequenc
interact
dc
receptor
inde
seen
nonenvelop
virus
mention
section
would
candid
chimer
vlpbase
vaccin
quit
varieti
vector
employ
bear
antigen
interest
tabl
rang
chimer
peptid
construct
virus
bacteria
one
valu
employ
nonenvelop
viru
particl
chimer
construct
potenti
display
heterolog
antigen
allow
target
immun
system
via
homolog
heterolog
viral
ligand
receptor
dc
good
exampl
approach
report
applic
porcin
parvoviru
porcin
circoviru
type
tabl
employ
homolog
vaccin
deliv
heterolog
epitop
biodegrad
polym
poli
lacticcoglycol
acid
plga
appli
proteinbas
vaccin
deliveri
decad
addit
polyethyleneimin
pei
load
plga
carrier
well
histidinerich
polym
lipid
use
nucleic
acid
deliveri
polym
offer
main
advantag
vaccin
vector
describ
section
well
base
virus
bacteria
product
biodegrad
polym
induc
strong
durabl
immun
respons
moreov
effici
degrad
nontox
metabolit
primarili
via
kreb
cycl
particul
carrier
also
flexibl
design
composit
structur
led
demonstr
high
potenti
vaccin
carrier
design
particl
employ
number
compon
main
one
plga
pegplga
pla
pegpla
hydrophobis
cholesterol
polycation
formul
list
review
topic
found
tabl
particul
formul
offer
wide
applic
vivo
deliveri
rout
addit
use
parenter
deliveri
transloc
nanoand
microparticl
system
immun
tissu
observ
intranas
administr
mice
concomit
develop
immun
respons
import
consider
respect
particl
size
appear
determin
perform
biodegrad
particl
vaccin
deliveri
particul
vaccin
deliveri
also
success
via
oral
rout
exampl
review
ohagan
et
al
moreov
oral
nasal
deliveri
chitosan
microparticl
compar
respect
diphtheria
vaccin
efficaci
mice
despit
advanc
high
applic
valu
littl
inform
biolog
characterist
dc
interact
process
particlebas
vaccin
moreov
analys
requir
vaccin
construct
activ
danger
recognit
dc
necessari
promot
dc
matur
develop
activ
immun
prrsv
virul
test
mice
test
primarili
mice
review
applic
nanoparticl
vaccin
deliveri
system
nanoparticl
microparticl
vaccinedeliveri
system
implic
nanoparticlesmicroparticl
mucos
vaccin
deliveri
use
solubl
polym
polym
microparticl
provid
improv
vaccin
respons
parenter
mucos
deliveri
vaccin
deliverycurr
trend
futur
polylactidecoglycolid
microparticl
surfac
adsorb
antigen
vaccin
deliveri
system
nanoparticl
carrier
nasal
vaccin
deliveri
biodegrad
poli
lacticcoglycol
acid
microparticl
inject
deliveri
vaccin
antigen
dnaload
biodegrad
microparticl
vaccin
deliveri
system
interact
dendrit
cell
immunolog
aspect
polym
microspher
vaccin
deliveri
system
microparticl
vaccin
adjuv
deliveri
system
recent
develop
vaccin
deliveri
system
recent
advanc
vaccin
adjuv
microparticl
vaccin
approach
stimul
mucos
immunis
chitosan
deriv
mucos
drug
vaccin
deliveri
nanoparticl
microparticl
drug
vaccin
deliveri
recombin
virus
employ
porcin
vaccin
deliveri
tabl
regard
nanoparticlebas
vaccin
inde
adenoviru
vector
effect
nanoparticl
deliv
dna
vaccin
context
capac
adenoviru
target
particular
receptor
dc
offer
potenti
defin
vaccin
target
immun
system
taken
field
biodegrad
particlebas
vaccin
deliveri
vehicl
see
section
similarli
vlp
tabl
nanoparticl
carri
protein
vaccin
cargo
albeit
form
integr
part
viral
structur
inde
bacteriophag
express
fmdv
protein
togeth
express
fmdv
refer
nanoparticl
surfac
geneprotein
display
system
insofar
biodegrad
vaccin
carrier
concern
much
less
inform
applic
porcin
vaccin
somewhat
surpris
consid
extent
applic
human
vaccin
vaccin
test
murin
model
see
review
list
tabl
nevertheless
number
articl
demonstr
potenti
biodegrad
carrier
deliveri
porcin
vaccin
tabl
also
includ
chitosanbas
nanoparticl
entrap
plasmid
carri
immunomodulatori
cpgodn
motif
elabor
approach
seen
applic
chitosanbas
nanoparticl
carri
plasmid
encod
porcin
purpos
author
employ
net
posit
charg
chitosan
nanoparticl
entrap
dna
chitosan
polym
matrix
ionic
crosslink
zhao
et
al
test
deliveri
system
mice
coadminist
bival
vaccin
pasteurella
multocida
classic
swine
fever
viru
csfv
result
encourag
context
nanoparticledeliv
adjuv
enhanc
develop
specif
immun
resist
challeng
infect
interest
see
applic
nanoparticledeliv
adjuv
function
porcin
host
particularli
consid
differ
murin
porcin
immun
system
far
deliveri
vaccin
antigen
concern
earli
result
use
ovalbumin
model
show
consider
promis
vitro
porcin
dc
supplementari
fig
vivo
harwood
et
al
unpublish
result
applic
nucleic
acid
vaccin
demonstr
factor
consid
context
particledeliv
vaccin
import
influenc
particl
charg
posit
charg
particl
facilit
associ
nucleic
acid
also
protein
antigen
appropri
neg
charg
via
ionic
crosslink
particl
major
consider
anion
cation
particl
suffici
charg
avail
bind
cargo
particl
charg
also
import
concern
mode
effici
deliveri
vivo
exampl
macklin
et
al
success
employ
gold
particl
epiderm
deliveri
dna
vaccin
immunis
pig
influenza
viru
use
devic
particlemedi
gene
transfer
epidermi
neg
charg
nanoparticl
construct
also
show
high
potenti
deliveri
pig
skin
effici
permeat
pig
skin
obtain
neg
charg
particl
rang
size
nm
lead
author
propos
nanoparticl
potenti
deliveri
vector
transderm
vaccin
consid
nucleic
acid
must
deliv
target
cell
effici
transcrib
strong
candid
target
epitheli
fibroblast
muscl
cell
cell
divid
nuclei
would
increas
chanc
dna
entri
cell
nucleu
transcript
low
rate
nuclear
divis
dc
may
restrict
capac
handl
dna
vaccin
nevertheless
target
dna
vaccin
dc
success
appli
via
viral
bacteri
vector
exampl
adenovirus
target
dc
promot
transcript
dna
see
section
salmonella
typhimurium
vector
interact
effici
murin
dc
vitro
promot
express
encod
antigen
vitro
vivo
dna
vaccin
process
dc
less
promis
dna
appli
directli
dc
ceppi
et
al
show
porcin
dc
directli
transfect
dna
transloc
dna
nucleu
permit
transcript
franco
et
al
show
uptak
mycobacteri
dna
vaccin
human
macrophag
dc
appar
nuclear
transloc
protein
product
though
mrna
detect
monocyt
transfect
cell
could
induc
pbmc
prolifer
obtain
pbmc
patient
posit
neg
reactiv
mycobacteri
antigen
saccharomyc
cerevisia
none
test
particl
uptak
none
test
transcytosi
cell
gold
particl
influenza
viru
dna
vaccin
none
gene
gunbas
dna
vaccin
microspher
mycoplasma
hypopneumonia
prime
adjuv
boost
encapsul
antigen
immunis
mice
porcin
vaccin
andor
porcin
cytokinebas
adjuv
follow
direct
intraderm
inocul
mice
dna
vaccin
encod
influenza
viru
nucleoprotein
np
bot
et
al
found
mhc
class
ii
mhc
class
ii
cell
carri
np
antigen
howev
mhc
class
ii
insuffici
defin
dc
langerhan
cell
fibrocyt
import
activ
cytotox
tcell
also
mhc
class
ii
posit
interest
adopt
transfer
np
mhc
class
ii
cell
induc
cytotox
tcell
although
author
argu
result
rule
transloc
endocytos
materi
especi
consid
capac
dc
endocytos
free
antigen
also
antigenproduc
cell
crossprim
inde
watkin
et
al
conclud
egfp
synthesis
follow
dna
vaccin
sheep
leach
skin
associ
dc
affer
lymph
base
observ
plasmid
protein
found
lymph
cell
plasma
protein
detect
lymph
dc
number
group
sought
improv
consequ
dna
vaccin
interact
dc
mostli
murin
model
one
approach
encod
dcactiv
dcrecruit
cytokin
review
kutzler
weiner
case
dc
necessarili
target
vaccin
becom
involv
enhanc
attract
site
antigen
product
endocytosi
antigen
antigenproduc
cell
dc
also
directli
activ
dna
vaccin
cpg
motif
dna
interact
although
spi
et
al
show
activ
anoth
approach
increas
target
encod
antigen
rather
dna
inde
et
al
state
dc
show
limit
capac
uptak
dna
vaccin
solut
encod
antigen
igg
fc
fusion
protein
vaccin
mice
promot
interact
fcr
dc
nchinda
et
al
gu
et
al
employ
similar
approach
mice
use
dna
encod
fusion
protein
singl
chain
fv
antibodi
specif
dc
receptor
dec
fusion
protein
heat
shock
protein
target
moieti
process
consid
target
vaccin
deliveri
vehicl
context
dna
vaccin
much
work
perform
use
gold
particlebas
deliveri
particularli
mice
although
mani
studi
mention
dc
key
player
promot
immun
respons
develop
major
directli
quantifi
vaccin
interact
dc
major
point
critic
rais
lauterbach
et
al
sought
elabor
question
use
dna
construct
either
ubiquit
express
cmv
promot
specif
express
dc
promot
follow
biolist
vaccin
mice
dnacoat
gold
particl
form
construct
effici
induc
antibodi
respons
howev
dna
encod
dcspecif
express
insuffici
induc
optimum
lymphocyt
respons
porgador
et
al
also
note
lymph
node
cell
directli
express
dnaencod
antigen
follow
vaccin
mice
rare
find
dc
carri
encod
peptid
lead
propos
dc
involv
crossprim
materi
produc
transfect
myeloblast
gold
particl
vaccin
deliveri
problemat
due
nonbiodegrad
risk
persist
toxic
problem
biodegrad
micronanoparticl
deliveri
also
promot
target
dna
vaccin
dc
howev
mani
articl
use
observ
immun
respons
gener
antigen
encod
dna
evid
target
dc
exampl
see
review
jilek
et
al
rather
specul
consid
proof
hand
biodegrad
particl
interact
effici
dc
review
jilek
et
al
insofar
dna
vaccin
deliveri
concern
convinc
work
come
vitro
studi
use
cell
line
jilek
et
al
success
transfect
murin
dc
line
plga
microparticl
carri
dna
encod
green
fluoresc
protein
gfp
howev
number
cell
express
gfp
low
author
relat
requir
dna
escap
phagosom
wherein
plga
particl
would
degrad
critic
point
consid
cytosol
localis
phagosom
contrast
cellular
localis
dna
transcript
machineri
inde
walter
merkl
show
particl
transfect
effici
low
phagocyt
cell
compar
nonphagocyt
cell
biodegrad
particl
target
dc
vivo
observ
dc
macrophag
endocytosi
plga
microparticl
spleen
drain
lymph
node
vaccin
mice
howev
author
determin
encod
antigen
express
dc
nonimmun
cell
particl
found
lymphoid
nonlymphoid
organ
moreov
walter
merkl
propos
applic
biodegrad
particlebas
dna
deliveri
vivo
like
lead
transfect
nonphagocyt
cell
fibroblast
although
much
work
date
mice
dna
vaccin
report
pig
dincer
et
al
analys
epiderm
deliveri
dnagold
particl
pig
minipig
antigen
express
detect
earli
h
postvaccin
uncertain
reflect
interact
dna
nonimmun
cell
nevertheless
one
conclud
particlebas
dna
vaccin
success
pig
applic
dnaload
plga
microparticl
may
futur
porcin
vaccin
consid
promis
shown
studi
mice
guinea
pig
nonhuman
primat
human
review
jilek
et
al
particl
target
dc
certain
dc
may
well
capabl
allow
dna
transcript
particlebas
deliveri
dna
vaccin
would
improv
target
nonimmun
cell
walter
merkl
porgador
et
al
suggest
cell
directli
target
particl
dna
transcript
may
nonphagocyt
cell
one
may
also
consid
report
differ
seen
process
dna
rna
dc
work
would
suggest
rna
vaccin
higher
potenti
biodegrad
particlebas
deliveri
dc
certainli
dc
accommod
rna
translat
promot
process
deriv
protein
induct
specif
immun
therefor
interest
see
work
advanc
biodegrad
nanoparticl
enhanc
uptak
rna
porcin
dc
supplementari
fig
target
vaccin
dc
potenti
biodegrad
particl
target
number
report
vaccin
carrier
target
dc
primarili
murin
human
field
gamvrelli
et
al
review
number
vaccin
construct
could
facilit
uptak
dc
order
pursu
topic
respect
target
vaccin
porcin
dc
necessari
appreci
advanc
made
murin
human
field
current
work
seek
character
dc
interact
vaccin
carrier
particularli
biodegrad
nanoparticl
carrier
high
potenti
applic
across
number
speci
differ
vaccin
due
uptak
reli
rel
simpl
compon
ionic
charg
carbohydr
moieti
particl
structur
particl
size
rather
peptidebas
lipoproteinor
glycoproteinbas
entiti
case
mani
viral
vector
moreov
biodegrad
particl
lend
readili
modif
design
decor
carri
specif
ligand
target
dc
receptor
fig
biodegrad
particl
structur
modifi
analys
term
influenc
dc
endocytosi
intracytoplasm
deliveri
vaccin
cargo
employ
carrier
protein
nucleic
acidbas
vaccin
tabl
also
carrier
adjuv
tabl
two
approach
combin
effici
mutual
target
vaccin
adjuv
may
achiev
target
vaccin
dc
necessari
concomitantli
deliv
danger
signal
promot
activ
matur
dc
system
depend
danger
signal
may
desir
codeliv
vaccin
particl
use
two
differ
particleson
vaccin
target
exampl
cdc
one
adjuv
target
exampl
pdc
attempt
concomit
deliveri
vaccin
adjuv
dc
like
dna
vaccin
would
appropri
vaccin
choiceprotein
rna
vaccin
may
greater
potenti
rna
vaccin
also
need
target
cell
unlik
dna
requir
divid
nucleu
translat
encod
gene
protein
dc
certainli
accommod
rna
translat
wit
dc
transfect
rna
encod
complet
genom
sequenc
classic
swine
fever
viru
csfv
fmdv
unfortun
rna
effici
enter
dc
without
assist
electropor
lipofect
allow
deliveri
rna
applic
techniqu
vivo
applic
except
one
relat
lipofect
applic
liposom
vaccin
deliveri
respect
nanoparticl
offer
high
potenti
rna
deliveri
dc
dna
deliveri
epitheli
muscl
cell
element
must
consid
appli
nanoparticl
target
protein
rna
vaccin
dc
influenc
target
cellular
site
vaccin
deliveri
protein
ideal
deliv
acidifi
endosom
system
promot
process
present
associ
mhc
class
ii
th
lymphocyt
process
associ
mhc
class
lead
activ
tc
lymphocyt
differ
intracellular
localis
requir
case
rna
cytosol
deliveri
requir
ensur
deliv
rna
degrad
cellular
rnase
plga
particl
report
escap
endosom
deliv
payload
cytoplasm
nevertheless
process
cellular
uptak
retent
process
well
character
particul
vaccin
deliveri
vehicl
interact
dc
certainli
case
particl
decor
target
andor
activ
prr
dc
would
influenc
deliveri
intracellular
compart
pertin
choos
target
ligand
good
exampl
comparison
materi
deliv
ligat
receptor
compar
ligat
mannos
receptor
target
lead
antigen
recycl
late
endosom
wherea
ligat
mannos
receptor
may
promot
recycl
process
peripher
endosom
compart
simpl
approach
dc
target
applic
antibodi
defin
dc
receptor
clear
potenti
target
ligand
overal
applic
approach
less
certain
whether
human
porcin
vaccin
heterolog
antibodi
risk
induc
immun
respons
host
isolog
antibodi
pose
problem
immun
complex
vaccin
latter
one
consid
remov
fc
portion
antibodi
prevent
interact
fcr
cell
innat
immun
defenc
nevertheless
antibodi
interact
vaccin
carrier
would
role
play
case
natur
humor
respons
antigen
immun
complex
format
would
push
equilibrium
immun
respons
toward
memori
develop
exampl
antibodybas
dctarget
seen
siglec
sialic
acidbind
immunoglobulin
superfamili
lectin
receptor
primarili
express
cell
immun
system
siglec
bind
specif
glycan
structur
contain
sialic
acid
murin
pdc
target
ovalbumin
conjug
antisiglech
antibodi
effici
endocytosi
ovalbumin
observ
lead
stimul
lymphocyt
receptor
also
target
specif
antibodi
enhanc
endocytosi
fab
fragment
mediat
rapid
uptak
earli
endosom
human
monocyt
one
note
siglec
famili
distribut
throughout
immun
system
mani
actual
inhibitori
receptor
carri
immunoreceptor
tyrosinebas
inhibitori
motif
itim
one
receptor
human
dc
human
dc
monocyt
contrast
siglech
actual
lack
tyrosinebas
signal
motif
cytoplasm
tail
function
effici
endocyt
receptor
murin
pdc
macrophag
observ
antisiglech
antibodi
target
anoth
receptor
famili
carri
itim
express
human
macrophag
dc
lysin
residu
transmembran
domain
interact
dnax
activ
protein
interestingli
express
appear
conserv
among
speci
anoth
import
characterist
siglec
express
dc
modul
associ
matur
cell
modul
also
note
anoth
glycanbind
dc
receptor
famili
bgalactosidebind
galectin
maturationdepend
modul
also
seen
express
ctype
lectin
receptor
dc
contrast
mani
galectin
siglec
reaction
express
ctype
lection
receptor
downregul
dc
matur
phenomenon
relat
reduc
antigen
uptak
matur
dc
ctype
lectin
receptor
dcsign
also
target
use
specif
antibodi
murin
primat
model
vaccin
deliveri
exampl
addit
use
antibodi
dc
receptor
vaccin
target
number
ligand
particular
receptor
identifi
offer
potenti
vaccin
target
preferenti
recogn
galectin
bind
glycoconjug
contain
bgalactos
structur
howev
uncertain
vaccin
particl
interact
differ
siglec
would
signal
dc
would
influenc
outcom
vaccin
handl
cell
interact
vaccin
siglec
carri
itim
would
necessarili
detriment
vaccin
target
yet
certain
dc
would
respond
vaccin
use
siglec
ligand
target
purpos
exampl
carri
itim
report
bind
human
red
blood
cell
solubl
sialoglycoconjug
siglech
lack
tyrosinebas
signal
motif
endocytos
lead
process
present
captur
antigen
yet
siglec
signal
intracellularli
via
adaptor
associ
lead
reduc
pdc
respons
tlr
ligand
also
signal
via
suggest
signal
impli
deliveri
activ
signal
cell
anoth
receptor
report
receptor
porcin
reproduct
respiratori
syndrom
viru
prrsv
bind
internalis
porcin
macrophag
consid
viru
interact
receptor
would
lead
internalis
target
may
prove
use
vaccin
target
strategi
also
express
dc
upregul
matur
cell
along
well
two
also
number
ligand
defin
ctype
lectin
receptor
dcsign
would
provid
use
target
moieti
exampl
glcnac
gal
glcr
oligosaccharid
form
outer
core
neisseria
meningitidi
lipopolysaccharid
gal
fuc
glcnac
fuc
gal
fuc
glcnac
determin
relat
glycosphingolipid
schistosoma
mansoni
respect
studi
neisseria
meningitidi
lipopolysaccharid
interact
dcsign
mannan
nacetylglucosamin
glcnac
found
interfer
bacteri
bind
mannan
includ
oxid
reduc
deriv
enhanc
antigen
target
endocytosi
dc
result
activ
dc
immun
respons
induct
vivo
least
mous
moreov
differenti
applic
oxid
reduc
form
mannan
favour
type
respons
respect
certainli
mannan
mannosyl
structur
bind
mannos
receptor
well
dcsign
employ
target
mannosebind
ctype
lectin
dc
tabl
number
vaccin
antigen
also
offer
target
facil
mannosecontain
moieti
inher
structur
either
synthet
structur
conjug
vaccin
deliveri
vehicl
approach
found
favour
mannosyl
biodegrad
nanoparticl
vaccin
carrier
relat
approach
ligand
ctype
lectin
siglec
receptor
also
possibl
target
dc
receptor
includ
tlr
fig
import
adjuvantdepend
activ
cell
certainli
tlr
ligand
chemic
defin
lipopeptid
potenti
adjuv
although
lipopeptid
report
term
vaccin
deliveri
pig
lipopeptid
lipoprotein
test
adjuv
potenti
employ
either
integr
antigen
compon
vaccin
admix
vaccin
antigen
classic
manner
disadvantag
lipoprotein
antigen
contrast
lipopeptid
synthet
compound
base
tripalmitoylsglyceryl
cystein
pam
cy
dipalmitoylsglyceryl
cystein
pam
cy
tend
serv
primarili
pamp
dimer
thu
allow
applic
gener
sens
relat
area
applic
lipidbas
vaccin
carrier
liposom
liposom
vaccin
deliveri
applic
adjuv
wide
report
murin
human
studi
vlp
also
construct
bear
lipopeptid
surfac
structur
infer
capac
homoand
heterodim
bind
structur
allow
potenti
vaccin
target
activ
dc
overview
particul
vaccin
target
immun
system
present
current
knowledg
concern
relationship
surfac
structur
vaccin
deliveri
vehicl
manner
dc
interact
particl
cargo
although
evid
vaccin
target
dc
high
potenti
porcin
vaccin
inform
come
infer
work
murin
human
dc
therein
major
effort
made
develop
viral
synthet
vaccin
carrier
critic
import
consider
therein
receptor
ligat
influenc
characterist
vaccin
interact
dc
whether
protein
rna
deliveri
employ
antigen
ultim
present
dc
deliv
carrier
translat
deliv
rna
process
via
endosom
recycl
process
accordingli
current
research
vaccin
target
dc
seek
determin
influenc
vaccin
deliveri
vehicl
surfac
decor
modul
dc
activ
link
cytosol
localis
deliv
vaccin
cargo
differ
protein
cargo
compar
rna
cargo
key
element
defin
manner
target
dc
promot
appropri
deliveri
lead
efficaci
immun
defenc
develop
supplementari
fig
tabl
mannosyl
nanoparticlemicroparticlebas
vaccin
enhanc
target
immun
system
ovalbumin
mannosyl
cation
nanoparticl
emulsifi
wax
plu
ctab
cation
surfact
mannosyl
nanoparticl
without
entrap
endosomolyt
agent
dioleoyl
phosphatidylethanolamin
dope
cholesterol
dna
vaccin
